Using JAK Inhibitors for Myelofibrosis
"We are thankfully starting to be blessed with more options than we've ever had," but "in the frontline proliferative setting, ruxolitinib has remained the standard of care."
Stay updated with breaking news from Stem Cell Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
"We are thankfully starting to be blessed with more options than we've ever had," but "in the frontline proliferative setting, ruxolitinib has remained the standard of care."
Explore the current landscape of AMD cell therapy, future prospects and challenges for this exciting emerging technology
ELK CITY, Idaho, September 11, 2023--Therapeutic Solutions International, Inc. (TSOI), announced today the development of a new therapeutic approach for treatment of Frontotemporal Dementia, by combining the activation of endogenous anti-inflammatory cells in the nervous system, together with regenerative cell intervention in the form of stem cell therapy, and molecules capable of activating endogenous stem cells already present in the patient.
The GENESIS trial reported substantially better stem cell mobilization when patients with multiple myeloma received motixafortide alongside filgrastim.
Experts recently debated whether additional intensive therapy can improve posttransplant outcomes for patients with acute myeloid leukemia who have residual disease after induction therapy.